Management of Nocturnal Enuresis in BPH
Start with alpha-blocker therapy (tamsulosin or alfuzosin) as first-line treatment, and if nocturia persists despite adequate voiding symptom control, add low-dose desmopressin (0.05-0.4 mg at bedtime) specifically targeting nocturnal polyuria. 1, 2
Initial Diagnostic Approach
The critical first step is determining whether the nocturnal enuresis stems from bladder outlet obstruction, nocturnal polyuria, or both. Obtain a 3-day bladder diary to calculate nocturnal polyuria index (nocturnal urine volume/24-hour total volume). 3, 4 If >33% in men over 65 years or >20% in younger men, nocturnal polyuria is present and requires specific treatment beyond standard BPH management. 5
Measure post-void residual and complete IPSS questionnaire to assess baseline voiding dysfunction severity. 1
Treatment Algorithm
Step 1: Alpha-Blocker Monotherapy
Begin with an alpha-blocker (tamsulosin, alfuzosin, or silodosin) to address the dynamic component of bladder outlet obstruction. 6, 1 This reduces smooth muscle tone in the prostate and bladder neck. Reassess at 4-12 weeks with repeat IPSS and bladder diary. 1
Step 2: Add 5-Alpha Reductase Inhibitor (if prostate >30cc)
If the prostate is enlarged (>30cc on ultrasound) and symptoms persist, add finasteride or dutasteride to address the static component through prostate volume reduction. 1 This combination reduces nocturia frequency by approximately 44.6% compared to alpha-blocker alone. 2
Step 3: Add Desmopressin for Persistent Nocturia with Nocturnal Polyuria
If nocturia persists despite adequate daytime voiding symptom control and bladder diary confirms nocturnal polyuria, add low-dose oral desmopressin (0.05-0.4 mg) at bedtime. 2, 3 This directly addresses insufficient antidiuretic hormone secretion causing nighttime urine overproduction.
- Desmopressin alone reduces nocturia by 43% 2
- Combined with alpha-blockers, nocturia decreases by 64.3% vs 44.6% with alpha-blocker alone 2
- First undisturbed sleep period increases from 82 minutes to 160 minutes with combination therapy 2
Critical Safety Considerations
Monitor serum sodium before initiating desmopressin and at 1 week, then monthly for 3 months. 2, 3 Hyponatremia occurs in 4.4-5.7% of patients. Educate patients to limit fluid intake 1 hour before bedtime and avoid excessive nighttime drinking. 2
Contraindications include:
- Baseline hyponatremia (<135 mEq/L)
- Uncontrolled heart failure
- Syndrome of inappropriate ADH secretion
- Severe renal impairment
Alternative Considerations
If storage symptoms (urgency, frequency) predominate alongside nocturia, consider adding anticholinergics or beta-3 agonists (mirabegron) to alpha-blocker therapy, though this addresses bladder overactivity rather than nocturnal polyuria specifically. 1, 4 Check post-void residual before and during treatment to monitor for urinary retention risk.
For patients with erectile dysfunction, PDE5 inhibitors (tadalafil 5mg daily) can be used as initial monotherapy or combined with alpha-blockers, providing modest nocturia reduction. 6, 4
Common Pitfalls
Do not assume all nocturia in BPH patients is due to prostatic obstruction. 7, 8 Up to 80% have nocturnal polyuria as a contributing or primary factor. 3 Treating only the prostate without addressing nocturnal polyuria leaves the core problem unresolved.
Do not use desmopressin without first documenting nocturnal polyuria via bladder diary. 5 This medication is ineffective for nocturia caused purely by reduced bladder capacity.
Recognize that nocturia may signal systemic conditions including sleep apnea, heart failure, diabetes, or circadian rhythm disruption requiring broader evaluation beyond urological management. 7, 8